An open‐label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people
Abstract A drug-drug interaction (DDI) trial of cytochrome P450 3A (CYP3A) is a necessary part of early‐phase trials of drugs mainly metabolized by this enzyme, but CYP3A DDI clinical trials do not have a standard design, especially for Chinese people. We aimed to offer specific recommendations for...
保存先:
主要な著者: | , , , , , , |
---|---|
フォーマット: | 図書 |
出版事項: |
Wiley,
2024-08-01T00:00:00Z.
|
主題: | |
オンライン・アクセス: | Connect to this object online. |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|
インターネット
Connect to this object online.3rd Floor Main Library
請求記号: |
A1234.567 |
---|---|
所蔵 1 | 利用可 |